Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Confirmatory Trial for Its Lead Drug, "DiaPep277" for Type 1 Diabetes

12 Sep 2012

·www.biospace.com

YAVNE, Israel, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. ( ) announced today that it has completed patient recruitment in its' DIA-AID 2, a confirmatory Phase III clinical trial using DiaPep277® for the treatment of Type 1 diabetes.

Organizations

Andromeda Biotech Ltd.

Andromeda Medizinische Systeme GmbH

Indications

Diabetes Mellitus, Type 1

Targets

Drugs

DiaPep-277

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.